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Most clinically used opioids are mu-opioid receptor agonists. Therefore, genetic 
variation of the OPRM1 gene that encodes the mu-opioid receptor is of interest. An 
amino acid changing polymorphism 118A>G (rs1799971) within the OPRM1 gene 
affects the function of the receptor.
We studied the association between the 118A>G polymorphism and oxycodone 
analgesia and pain sensitivity in 1,000 women undergoing breast cancer surgery. 
Preoperatively, experimental cold and heat pain sensitivity was tested. Postoperative 
pain was assessed at rest and during motion. I.v. oxycodone analgesia was titrated 
first by a research nurse and on the ward using a patient controlled analgesia device. 
The primary endpoint was the amount of oxycodone needed for the first state of 
adequate analgesia. The 118A>G polymorphism was genotyped using Sequenom 
MassArray. The association between this variant and the pain phenotypes was 
tested using linear regression.
The 118A>G variant was significantly associated with the amount of oxycodone 
requested for adequate analgesia (P=0.001, β=0.016). Oxycodone consumption was 
highest in the individuals having the GG genotype (0.16 mgkg-1) , lowest in the AA-
group (0.12 mg kg-¹) while the AG-group was in between (0.13 mg kg-¹). The G allele 
was also associated with higher postoperative baseline pain ratings (P=0.001, 
β=0.44). No evidence of association with the other examined pain phenotypes was 
seen.
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21 Introduction
Increasing interest is being focused on genetic factors that are known to modify 
pain sensitivity and analgesic responses. 37 An example is the 118A>G 
polymorphism (rs1799971) in the OPRM1 gene on chromosome 6 coding for the 
mu-opioid receptor. This polymorphism leads to asparagine being replaced by 
aspartate, which changes the N-glycosylation of the protein. 2, 13 The polymorphism 
is relatively common, having a frequency around 10-15% in the European 
populations, but there is also large interethnic variability in the allele frequency. 34 
This amino acid change alters the binding potential and half-life of the receptor and 
thereby modulates the downstream functions of the receptor. 2, 6, 13 Also 
contradictory findings exist and it seems possible that the molecular consequences 
of this polymorphism are cell or tissue type specific. 34 As 118A>G has the highest 
allelic frequency of all amino acid altering OPRM1 SNPs and the mu-opioid 
receptor conveys most of the opioid effects this polymorphism could significantly 
influence the response to opioid therapy.
Opioids are the most commonly used analgesics for moderate to severe pain. 32 So 
far the impact of genetic variation of the mu-opioid receptor in analgesia has 
remained controversial. Several studies have associated the 118A>G 
polymorphism to increased opioid consumption and pain sensitivity 29, 31 while 
others have failed to find any evidence of association between this polymorphism 
and opioid effectiveness or adverse effects. 22 Many studies have had small 
sample sizes 40 or a low frequency of the G-allele. 4
3A meta-analysis from 2009 concluded that the 118A>G polymorphism showed no 
overall association with opioid analgesia.35 However, that meta-analysis did not 
include any studies on oxycodone. In another recent meta-analysis the 
polymorphism was shown to be reproducibly associated with decreased opioid 
effects but due to the small effect size the clinical relevance of this association was 
questioned.34
Non-cancer related use of oxycodone, including intravenous administration, is 
increasing worldwide.14, 25 The association between postoperative oxycodone 
consumption and the mu-opioid receptor polymorphism has been addressed 
before in only one small study which found no association between the OPRM1
1118A>G polymorphism and postoperative oxycodone analgesia.40
The aim of our study was to assess the role of the OPRM1 118A>G polymorphism 
in postoperative oxycodone analgesia. Our study cohort consists of 1,000 well-
characterized women undergoing surgery for breast cancer. A study sample of this 
size should enable estimation of the true effect size of this variant. We also used 
the amount of oxycodone needed for the first state of adequate analgesia as the 
primary outcome for oxycodone analgesia as other measures of opioid 
consumption are likely to be influenced more by pharmacokinetic factors. In 
addition, we studied the role of the OPRM1 118A>G polymorphism in experimental 
pain sensitivity using both heat and cold stimulation.
42 Methods
2.1 Ethics
The coordinating ethics committee (136/E0/2006) and the ethics committee of the 
Department of Surgery (Dnro 148/E6/05) of the Hospital District of Helsinki and 
Uusimaa had approved the study protocol. All patients provided a written informed 
consent.
2.2 Patients
The patients were recruited from the Breast Surgery Unit, Helsinki University 
Central Hospital between August 2006 and December 2010. The cohort consists 
of 1,000 women (aged 18-75 years) diagnosed with unilateral non-metastasized 
breast cancer who were to undergo elective mastectomy or breast conserving 
surgery with sentinel node biopsy, axillary clearance or both. The type of surgery 
was decided based on tumor characteristics and the patient’s wishes. Patients 
scheduled for immediate breast reconstruction were excluded from the study.
Originally, 1149 of the 1536 eligible patients were invited to participate in the study 
(Figure 1). The remaining 387 patients could not be recruited for logistic reasons. A 
total of 126 patients declined and 23 were withdrawn due to a contraindication in 
the anaesthetic 
protocol, change in 
the type of surgery, 
violation of the 
study protocol or 
logistic reasons. 
The study cohort 
has been described 
in more detail by 
Kaunisto and 
others.18
52.3 Study procedure
The research nurse collected patient characteristics the day before the surgery. 
The background data included e.g. age, weight and height, number of previous 
operations (other than breast surgery) and previous chronic pain of any kind. 18 
Patients also answered psychological questionnaires, Beck Depression Inventory 1
and Spielberger State and Trait Anxiety Inventory. 30 Pain in the chest/axillary area 
was assessed using a numerical rating scale (NRS 0-10).
Before surgery the research nurse tested the patients for heat and cold pain 
sensitivity. In the heat pain test a 16 mm x 16 mm thermode (TSA-II NeuroSensory 
Analyzer, Medoc Ltd, Ramat Yishai, Israel) was set at 43˚C and 48˚C in this order 
and then held for 5 seconds on the volar side of the patient’s forearm contralateral 
to surgery. Patients were asked to rate the intensity of pain using a numerical rating 
scale (NRS 0-10) where the anchors were 0 for "no pain" and 10 for "worst pain 
imaginable". In the cold pain test (JULABO USA Inc., Allentown, PA) the patients 
immersed their hand in cold water (2-4˚) for the maximum time tolerated with a cut-
off time of 90 s. Pain intensity was assessed every 15 seconds using NRS. If the 
patient withdrew the hand before 90 s, the pain intensity was recorded as 10 at all 
the following time points. The cold pain test was not performed to the first 100 
patients because of unavailability of the device.
The anesthetic procedures were standardized. All patients were premedicated with 
diazepam 2.5-12 mg and acetaminophen 1 g orally, and anesthetized with 
intravenous propofol and remifentanil. At the end of surgery all patients received 1 
µg kg-1 fentanyl iv. At the same time point they were given ondansetron 4 mg i.v. 
and droperidol 0.01 mg kg-¹ i.v. to prevent postoperative nausea and vomiting. A 
blood sample was collected from the patients for DNA isolation before transfer to 
the post anesthesia care unit (PACU).
6In the PACU the patients were asked to rate the pain intensity at rest and during 
movement using NRS 0-10. Motion pain was assessed by asking the patient to 
raise the arm ipsilateral to surgery up to 90˚. Analgesia was titrated by the research 
nurse who asked about the pain intensity every 5 minutes and administered 1-3 mg 
oxycodone until the patient rated the pain intensity <4 (NRS 0-10) or indicated 
otherwise that pain relief was adequate. Afterwards pain intensity was assessed 
every 15 min until the patient needed a new dose of oxycodone.
After two hours the patients were transferred to the ward and analgesia was 
provided with a patient-controlled analgesia device (PCA, Abbott Pain 
Management ProviderT, Abbott Laboratories, North Chicago, IL, USA, or CADD-
LegacyT, Deltec, Inc., St. Paul, MN, USA) for up to 20 hours except for the 
outpatients (N=70). The total consumption of oxycodone was recorded (post 
anesthesia care unit and PCA). All patients were given acetaminophen 1g orally 
every eight hours as a basic analgesic.
2.4 Genotyping
DNA was extracted from peripheral blood using the Autopure LS automated DNA 
purification instrument (Gentra Systems, Inc., Minneapolis, MN, USA). OPRM1
118A>G (rs1799971) was genotyped using the Sequenom MassARRAY system 
and the iPLEX Gold Single Base Extension chemistry (Sequenom, San Diego, CA, 
USA).16 Both duplicate, positive and negative control samples were included in 
each DNA plate to confirm the accuracy of the genotyping results. Genotyping was 
performed blind to phenotypic information.
2.5 Statistical analysis
2.5.1 Power calculations
Post-hoc power calculations were conducted to estimate the size of the effect the 
118A>G polymorphism should have on the studied phenotypes for our study 
7sample to have power to detect the effect. Calculations were performed using the 
freely available Quanto software, version 1.2.4. 33 Calculations were done using 
values retrieved from our study (minor allele frequency 0.17, means and standard 
deviations of the quantitative traits seen in our data). The level of significance was 
set to P=0.05.The options in effect were an additive genetic model and 
independent individuals.
2.5.2 Genetic association analyses
Statistical significance for assessing Hardy-Weinberg equilibrium for the OPRM1
polymorphism was obtained using Plink software. 27 Association between the 
OPRM1 A118>G polymorphism and studied phenotypes was evaluated using 
linear regression. An additive model was used. In the additive model, heterozygous 
individuals are assumed to have a phenotypic value between the two homozygous 
groups. Since all outcomes did not follow normal distribution, the results were 
confirmed with a permutation testing strategy. For this we used the max(T) 
permutation option of the Plink software. Each model was fitted 10.000 times and 
the original statistics were compared with the test statistics received from 
permutation.
The primary phenotype was the amount of oxycodone (mg kg-¹) the patients 
requested in order to achieve the first state of adequate analgesia. This phenotype 
was chosen to minimize possible pharmacokinetic effects at later time points.17
Secondary phenotypes included total oxycodone consumption during 20 h (mg kg-
¹), baseline postoperative pain (first measurement after waking up), postoperative 
pain during movement when the patient needed the first dose of oxycodone and 
time from emergence from anesthesia to the first state of adequate analgesia. 
Furthermore, three experimental pain phenotypes were studied; cold pain intensity 
at 15s (NRS), heat pain intensity (NRS) and the total time the patients held their 
hand in cold water. Age, body mass index (BMI), state anxiety score, chronic pain 
and the type of surgery were used as covariates when analysing the association 
8between the phenotypes and genotypes. These covariates were selected based on 
our previous findings so that the factors showing corrected p-values ≤0.001 in the 
linear regression analysis for at least one of the phenotypes studied here were 
included. 18 The 70 day surgery patients were removed from the analysis when 
assessing total oxycodone consumption as they did not use the PCA system.
The P-value for the primary phenotype was not corrected because only one test 
was performed. The P-values for the secondary phenotypes were Bonferroni 
corrected with the number of all tests performed (nine phenotypes). The level of 
statistical significance was set at a corrected empirical P<0.05.
2.5.3 Multiple linear regression
Data were analyzed using the R program package version 2.14.2. Multiple Linear 
Regression models were created to evaluate the effect of the 118A>G 
polymorphism together with other variables on the amount of oxycodone (mg kg-¹) 
the patients requested in order to achieve the first state of adequate analgesia and 
on total oxycodone consumption during 20 h. The variables studied include type of 
surgery, age, BMI, state anxiety and the presence of any pre-operative chronic pain 
condition. Linear modeling was done both including and without the 118A>G 
polymorphism to be able to estimate the effect of the polymorphism alone. The 
effect of the whole model on the studied variables i.e. the proportion of the total 
variance explained is presented using a multiple r-squared value.
3 Results
3.1 Patient characteristics
Patient characteristics grouped by the OPRM1 118A>G genotype are shown in 
Table 1.The groups did not differ significantly for any of the studied variables. A 
total of 993 subjects were included in the analysis since genotyping was 
9AA (n=631) AG (n=327) GG (n=35) p-value
Age (year) 56.7 (9.2) 57.4 (9.2) 57.7 (10.7) 0.262
Height (cm) 165 (6.1) 164.7 (5.8) 164.8 (5.1) 0.503
Weight (kg) 68.9 (12.1) 69.3 (12.3) 70.7 (8.9) 0.402
BMI 25.3 (4.3) 25.5 (4.3) 26.1 (3.3) 0.302
40.6 (11.4) 40.2 (10.9) 36.2 (10.2) 0.118
63.4% / 36.6% 62.1% / 37.9% 51.4% / 48.6%
45.0% / 55.0% 40.7% / 59.3% 57.1% / 42.9%
20.9% / 79.1% 30.3% / 69.7% 22.9% / 77.1%
Table 1. Demographic means and SDs from study patients by OPRM1  118A>G genotype
Anxiety score
Type of surgery (breast 
conserving surgery/mastectomy)
Sentinel biopsy/axillary clearance 
Preoperative chronic pain 
condition (yes/no)
unsuccessful in seven subjects. The majority of the patients underwent breast-
conserving surgery (n=626) with or without axillary clearance (206 and 420, 
respectively). The remaining 374 patients underwent mastectomy and of these 234 
had also axillary clearance. The effect of type of surgery on the amount of 
oxycodone needed for the first state of satisfactory analgesia is shown in Figure 2. 
The mean time from emergence from anesthesia to the first state of adequate 
analgesia was 36 min (range 0-132 min) and the mean dose required to achieve 
adequate analgesia was 0.13 mg kg-¹ (range 0-0.59 mg kg-¹).
3.2 Genetic association studies
Genotype counts and frequencies 
in our cohort were 631 for AA 
(63.5%), 327 for AG (32.9%) and 
35 for GG (3.5%). Genotypes 
were in Hardy-Weinberg 
Equilibrium (P=0.43). The allele 
frequencies were A=0.80 and 
G=0.20. The estimated effect 
sizes needed for our study to have 
sufficient power (80%) were 
reasonable. For the primary 
phenotype, the amount of 
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oxycodone needed for the first state of satisfactory analgesia, sufficient effect size 
was estimated to be 0.015 mg kg-¹ per minor allele. For total oxycodone 
consumption the estimated effect size was 0.069 mg kg-¹, for cold pain at 15 s 0.53 
NRS units and for cold pain tolerance 5.7 s per minor allele.
3.3 Postoperative pain
The association results for the postoperative phenotypes are shown in Table 2. The 
primary phenotype, the amount of oxycodone required by the patients for the first 
state of adequate analgesia showed a significant association with the 118A>G 
polymorphism (uncorrected P=0.001, β =0.016), with the GG-group requiring the 
largest (0.16 mg kg-¹) and the AA-group the lowest (0.12 mg kg-¹) amount of 
oxycodone. For the heterozygous individuals the required dose was closer to the 
AA-group, 0.13 mg kg-¹. The permuted P-value was also significant (P=0.001). The 
distribution of the required doses by genotype is shown in Figure 3. 
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AA AG GG Beta P-value
Empiric
al P-
Corrected 
P-value*
Primary phenotype
Oxycodone needed for first state 
of adequate analgesia (mg kg⁻¹) 0.12 (0.09) 0.13 (0.09) 0.16 (0.12) 0.016 0.001 0.001
Secondary postoperative phenotypes
Motion pain (NRS) 5.0 (1.4) 5.1 (1.5) 5.1 (1.6) 0.11 0.193 0.196 1
Oxycodone in PACU (mg kg⁻¹) 0.14 (0.09) 0.15 (0.09) 0.17 (0.11) 0.012 0.011 0.013 0.12
Total oxycodone (mg kg⁻¹) 0.25 (0.18) 0.25 (0.17) 0.27 (0.20) 0.005 0.581 0.597 1
Time to first satisfaction (mg kg⁻¹) 35.9 (16.4) 36.9 (15.1) 41.9 (17.0) 2.033 0.019 0.025 0.2
Cold pain intensity, 15 s  (NRS) 5.7 (2.8) 5.7 (2.9) 5.3 (3.3) -0.068 0.692 0.69 1
Cold total time(s) 46.6 (29.2) 45.6 (29.7) 56.0 (31.2) 1.16 0.507 0.498 1
Heat 48 ˚c (NRS) 3.5 (2.5) 3.5 (2.3) 3.8 (2.8) 0.011 0.934 0.935 1
Data are represented as means (SD). 
Secondary experimental pain phenotypes
Table 2. Mean values of the studied variables for each genotypic group and the association of OPRM1 
118A>G with the primary and the secondary phenotypes.
Association results are based on linear regression analysis using age, BMI, anxiety score, chronic pain and 
type of surgery as covariates. Additive model was used. Empirical P-values are produced by performing 
10.000 permutations.
* P-values for the secondary phenotypes are corrected for multiple testing using Bonferroni correction (eight 
phenotypes).
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There was no statistically significant difference in the total oxycodone consumption 
during the 20 h (uncorrected P=0.58, β =0.005), even though the GG-group 
needed slightly more oxycodone than the AA- or AG-groups (0.265 mg kg-¹ for AA 
and 0.249 mg kg-¹ for AG, respectively). The first (baseline) postoperative pain 
intensity value during movement showed associated with the G allele (uncorrected 
P=0.001, β =0.44). However, neither the postoperative pain intensity during motion 
when needing the first dose of oxycodone nor time from waking to satisfaction 
showed any evidence of association with the 118A>G polymorphism. 
3.4 Experimental pain
Data on experimental cold pain were available from 893 patients due to the 
unavailability of the device at the beginning of the study. No association was found 
13
between 118A>G and either cold or heat pain. Association results for experimental 
pain are shown in Table 2.
3.5 Multiple linear regression models
The created multiple linear models are presented in Table 3. The age of the patient 
(P=6.6x10-08) and the type of surgery performed (P=4.7 x 10-09) were very 
significant factors in explaining the overall variance in the amount of oxycodone the 
patients requested in order to achieve the first state of adequate analgesia. The 
118A>G polymorphism (P=0.0009) and anxiety (P=0.006) were also significantly 
associated. All these factors together explained approximately 12.6% of the 
variance. Based on the modelling results done excluding the polymorphism we 
concluded that although being a significant explaining factor, the 118A>G 
polymorphism alone explained less than 1% of the variance (data not shown). 
When a similar modeling approach was used for total oxycodone consumption, 
there was no evidence for the 118A>G polymorphism to be an explaining factor 
(P=0.706).
N (valid)
Covariate P-value Beta (SD) P-value Beta (SD)
Type of surgery 4.68 x 10-09 0.232 (0.027) 1.55x10-5 0.019 (0.004)
Age 6.60x10-08 0.013 (0.002) < 2x10-16 -0.005 (0.001)
BMI 1.30x10-06 -0.002 (0.0003) 5.40x10-5 -0.005 (0.001)
Chronic pain 0.398 -0.003 (0.001) 2.95x10-5 0.053 (0.013)
Anxiety score 0.006 0.005 (0.006) 2.70x10-5 0.002 (0.001)
OPRM1 118A>G 0.001 0.001 (0.0002) 0.706 0.004 (0.010)
Proportion of variance 
(r2) explained by the 
model
Table 3. Effects of each covariate on oxycodone consumption and the proportion of 
the total variance explained by the whole model. Beta shows the change in 
oxycodone consumption corresponding to each one unit increase in the covariate.
Oxycodone needed for 
satisfactory pain relief (mg kg-1)
Oxycodone, total (mg kg-1)
973 898
0.126 0.177
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4 Discussion
4.1 Postoperative opioid consumption
Our study shows wide variation in the individual oxycodone requirements in 
agreement with previous studies.21, 31, 36 Some patients needed no oxycodone in 
addition to acetaminophen given to all patients while some required 80 mg during 
the first 20 postoperative hours.
In our sample the 118A>G polymorphism showed a significant association with the 
amount of oxycodone required for the first state of adequate analgesia which was 
achieved during an average of 36 min. In order to have adequate analgesia the 
GG-individuals needed the largest amount of oxycodone but they did not report 
higher pain scores when needing the first dose. A number of studies have reported 
that the 118A>G polymorphism would affect postoperative pain scores.28, 29, 36 Also 
in our study the G allele was associated with higher postoperative baseline pain 
ratings when pain intensity was measured after surgery before titration of of pain 
relief with oxycodone was started. However, pain intensity scores cannot be used 
as outcome measures if the patients are titrated to adequate analgesia according 
to their needs as in our study. When using opioid consumption as a proxy for 
postoperative pain it is important to bear in mind that other factors such as opioid-
induced nausea may have an impact on the opioid dose. Our patients were 
premedicated with ondansetron and droperidol to prevent nausea.
Interestingly, we found no association between 118A>G polymorphism and the 
total oxycodone consumption during the first 20 h. This is in accordance with 
Zwisler and others 40 who performed the only previous study concerning OPRM1 
and postoperative oxycodone use in 268 patients of whom only four had the GG 
genotype. Our study showed a trend for the GG-group requiring the largest dose of 
oxycodone but this difference did not reach statistical significance. This might be 
because of the relatively low number of GG-individuals but also the effect size of 
15
the polymorphism, based on this data, was small – only 0.005 mg kg- ¹ per minor 
allele.
The difference between the two phenotypes (first state of adequate analgesia and 
total consumption of oxycodone over 20 h) in relation to their association with the 
genotype is quite interesting. It could be explained by the fact that the first state of 
adequate analgesia most closely reflects the amount of oxycodone needed to 
reach the mu-opioid receptors in the central nervous system to provide analgesia. 
The total consumption of oxycodone over 20 h may be affected by other important 
pharmacogenetic factors related to the pharmacokinetics of oxycodone. Previous 
studies have shown that adequate analgesia is achieved faster with intravenous 
oxycodone than morphine.17 This has been explained by pharmacokinetic factors 
as the steady state between plasma and brain concentrations is achieved faster 
with oxycodone than with morphine.23 Furthermore, pain intensity decreases with 
time rendering the study less sensitive. Thus, considering the low number of GG-
individuals the power of the study may not have been sufficient to show a 
difference at 20 h.
So far the impact of genetic variation of the mu-opioid receptor in analgesia has 
remained controversial. A meta-analysis published 2009 concluded the 118A>G 
polymorphism to be of minor importance.35 Yet several studies have associated the 
118A>G polymorphism to increased opioid consumption and pain sensitivity. 7, 8, 28, 
29, 31 In four studies large differences in total postoperative opioid consumption 
were seen.8, 28, 29, 31 All these studies had large sample sizes consisting of Asian 
patients and used morphine.  In Caucasian populations the effect has been smaller 
or non-existent.4, 11, 21, 40 The GG genotype is much rarer in the Caucasian 
population 21, 26, 40 compared with the Asian population 10, 19, 31 which may explain 
some of the difference. In addition, many of the negative studies have had small 
sample sizes 4, 9, 11 or a low frequency of the G-allele.3, 15, 21
Two previous studies have used a different approach to measure the effect of mu-
opioid receptor genotype on postoperative pain.5, 36 In these studies the amount of 
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opioids given to subjects has been standardized and the focus has been on the 
pain score. The study published by Wu and others 36 reported significantly higher 
pain scores in the AG- and GG-group during the first postoperative hour compared 
to the AA-group. This is in agreement with our results.
When considering the association of the 118A>G polymorphism with the amount of 
oxycodone needed for the patient to achieve satisfactory analgesia, the estimated 
effect size was 0.016 mg kg-¹ per minor allele. The GG-group required on the 
average 30% more oxycodone compared with the AA-group even though the GG-
group had a lower frequency of axillary clearances compared with the AA-group 
(Table 1). Axillary clearance was related to significantly more oxycodone 
consumption compared with sentinel biopsies (Figure 2).
There are many other factors affecting the need for analgesia as indicated in Table 
3 which also shows that type of surgery, age, BMI, previous chronic pain, anxiety 
and the 118A>G polymorphism explain only 12.6 to 17.7% of the variation in 
oxycodone requirements at the first state of satisfaction and over 20 h, 
respectively. The effect of these other significant explaining factors has been 
discussed in our previous study. 18 Also, acute postoperative pain is modulated by 
many biological processes and hence by many different genes.
4.2 Experimental pain
The association of 118A>G polymorphism with experimental pain has not been 
much studied. Three studies with low numbers of subjects 7, 38, 39 have associated it 
with higher pain thresholds for experimental pain caused by pressure, cold or 
electrical stimulation. Fillingim and others 7 reported that carriers of the G-allele had 
lower pain thresholds for mechanical stimuli than non-carriers. Their results also 
suggested a gender difference as females carrying the G-allele reported higher 
heat pain scores whereas men reported lower pain scores compared with AA-
17
individuals. A similar trend was reported by Lötsch and others.24 In our study there 
was no association between either experimental heat or cold pain sensitivity and 
the 118A>G polymorphism in agreement with Huang and co-workers.12 It is not 
surprising that the fairly low intensity stimulation with 48°C for 5 s did not show any 
association with the polymorphism. However, one would have expected an 
association in the cold pain test, which is very unpleasant and could activate 
stress-induced analgesia which is at least partly mediated by the endogenous 
opioid system. 20
5 Study limitations
This study was performed in female patients only. Therefore, no conclusions can 
be made regarding males. Even though our cohort was large, the number of 
individuals homozygous for the minor allele (GG) was still relatively low. This 
affects the power of our study to detect effects specific to the homozygous carriers. 
6 Conclusion
The mu-opioid receptor polymorphism 118A>G was associated with a significantly 
increased need for oxycodone in the early postoperative period but it was not 
associated with experimental pain sensitivity. Due to differences in allelic frequency 
of 118A>G the impact of this mutation is lower in the Caucasian population than in 
the Asian population. The higher allelic frequency of this polymorphism may render 
this mutation more eminent in the Asian population.
18
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